Acta Med. 2003, 46: 85-89

https://doi.org/10.14712/18059694.2019.12

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)

Ladislav Chrobák, Jaroslava Voglová

Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, 2nd Department of Medicine, Division of Clinical Hematology, Hradec Králové, Czech Republic

Received April 1, 2003
Accepted May 1, 2003

References

1. Biernaux C, Loos M, Sels A et al. Detection of major bcr-abl expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86:118–22.
2. Blagosklonny MV, Fojo T, Bhalla KN et al. The Hsp 90 inhibitor geldamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001; 15:1537–43. <https://doi.org/10.1038/sj.leu.2402257>
3. Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine tri-phosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who developed imatinib (STI 571) resistance. Blood 2002; 99:3472–5. <https://doi.org/10.1182/blood.V99.9.3472>
4. Cortes JE, Talpaz M, Giles F et al. High-dose imatinib mesylate (STI 571, Gleevec) in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon- alpha (IFN) induces molecular remission. Blood 2002; 100:Abstr. 616. <https://doi.org/10.1182/blood-2002-10-3154>
5. Dalay GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the Ph 210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824–30. <https://doi.org/10.1126/science.2406902>
6. Deininger MW, Goldman JM, Lydon N et al. The tyrosine kinase inhibitor CGP 57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90:3691–8.
7. Donato NJ, Wu JY, Stapley J et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI 571. Blood 2003; 101:690–8. <https://doi.org/10.1182/blood.V101.2.690>
8. Donato NJ, WU JY, Talpaz M. Novel tyrosine kinase inhibitors suppress BCRABL signaling and induce apoptosis in STI 571 sensitive and resistant CML cells. Blood 2002; 100:Abstr. 1434.
9. Drucker BJ. for IRIS (International Randomized INF vs STI-571 (Gleevec, Glivec, imatinib) versus interferon (INF) + cytarabin as initial therapy for patients with CML: results of randomized study. Proc Am Soc Clin Oncol 2002; 21:1a (Abstract).
10. Dorsey JF, Cunnick JM, Lanchart R et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 2002; 16:1589–95. <https://doi.org/10.1038/sj.leu.2402678>
11. Drucker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105:3–7. <https://doi.org/10.1172/JCI9083> <PubMed>
12. Drucker BJ, Sawyers CL, Katarjian H. Activity of a specific inhibitor of the BCRABL tyrosine kinase in the blast crises of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia Chromosome. N Engl J Med 2001; 344:1038–42. <https://doi.org/10.1056/NEJM200104053441402>
13. Drucker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031–7. <https://doi.org/10.1056/NEJM200104053441401>
14. Drucker BJ, Tamura S, Buchdunger E et al. Effect of a selective inhibitor of the abl tyrosine kinase on the growth of BCR-ABL positive cells. Nature Medicine 1996; 2:561–6. <https://doi.org/10.1038/nm0596-561>
15. Faderl S, Talpaz M, Estrov Z et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341:164–72. <https://doi.org/10.1056/NEJM199907153410306>
16. Bambacorti-Passerini C, Barni R, le Contre P et al. Role of alpha-1 acid glycoprotein in the in-vivo resistance of human Bcr-Abl+ leukemic cells to the Abl inhibitor STI 571. J Natl Cancer Inst 2000; 92:1641–50. <https://doi.org/10.1093/jnci/92.20.1641>
17. Gorre ME, Mohamed M, Elwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation and amplification. Science 2001; 293:876–80. <https://doi.org/10.1126/science.1062538>
18. Gorre ME, Sawyers CHL. Molecular mechanisms of resistance to STI 571 in chronic myeloid leukemia. Current Opin Hematol 2002; 9:303–7. <https://doi.org/10.1097/00062752-200207000-00007>
19. Graham S, Jörgensen H, Allan E et al. A significant proportion of CD 34+ progenitor cells survive exposure to STI 571 independent of their position in cell cycle. Blood 2001; 96:Abstr. 1482.
20. Hsiao LT, Chung HM, Lin JY et al. Steven-Johnson syndrome after treatment with STI 571: a case report. Br J Haematol 2002; 117:620–2. <https://doi.org/10.1046/j.1365-2141.2002.03499.x>
21. Kantarjian HM, Cortes J, O’Brien S. Imatinib mesylate (STI 571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99:3547–53. <https://doi.org/10.1182/blood.V99.10.3547>
22. Kantarjian HM, O’Brien S. Cortes JE et al. Imatinib-mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100:1590–5.
23. Kantarjian HM, O’Brien SM, Keating M et al. Results of decitabine therapy in accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997; 11:1617–20. <https://doi.org/10.1038/sj.leu.2400796>
24. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 246:645–52. <https://doi.org/10.1056/NEJMoa011573>
25. Kantarjian HM, Smith TL, O’Brien SM et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon – alpha therapy. Ann Intern Med 1995; 122:254–61. <https://doi.org/10.7326/0003-4819-122-4-199502150-00003>
26. Kantarjian HM, Talpaz M, O’Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101:473–5. <https://doi.org/10.1182/blood-2002-05-1451>
27. Kantarjian HM, Talpaz M, Santini V et al. Homoharringtonine history, current research, and future directions. Cancer 2001; 92:1591–1604. <https://doi.org/10.1002/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U>
28. Keating A. Chronic myeloid leukemia: current therapies and the potential role of farnesyl-transferase inhibitors. Semin Hematol 2002; 39(suppl.2):11–7. <https://doi.org/10.1053/shem.2002.35979>
29. Kelliher M, McLaughlin, Witte O et al. Induction of a chronic myelogenous leukemia – like syndrome in mice with V-abl and bcr/abl. Proc Natl Acad Sci USA 1990; 87:6659–63.
30. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041–50.
31. Konopka JB, Watanabe SM, Singer JW et al. Cell lines and clinical isolates derived from Ph21–positive chronic myelogenous leukemia patients express C-abl proteins with a common structural alteration. Proc Natl Acad Sci USA 1985; 82:1810–14. <https://doi.org/10.1073/pnas.82.6.1810> <PubMed>
32. Le Coutre P, Tassi E, Varella–Garcia M et al. Induction of resistance to Abelson inihibitor STI 571 in leukemic cells through gene amplification. Blood 2000; 95:1758–66.
33. Luzzatto L, Frassoni F, Melo JV. Imatinib: can one outwit chronic myeloid leukemia? Haematologica 2002; 87:898–900.
34. Luzzato L, Melo JV. Acquired resistance to imatinib mesylate: selection for preexisting mutant cells. Blood 2002; 100:1105. <https://doi.org/10.1182/blood-2002-05-1578>
35. Mahon FX, Deininger MWN, Schultheis B et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to tyrosine kinase inhibitor STI 571: diverse mechanism of resistance. Blood 2000; 96:1070–9.
36. Marin D, Marktel S, Bua M et al. The use of imatinib (STI 571) in chronic myeloid leukemia: some practical considerations. Haematologica 2002; 87:979–86.
37. Mauro MJ, O’Dwyer ME, Stone RM et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose Ara-C as initial therapy for newly diagnosed chronic phase CML. Blood 2002; 100:Abstr. 617.
38. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88:2375–84.
39. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 32:1497.
40. O’Briens S, Kantarijan H, Keating M et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86:3322–6.
41. Ottmann OG, Drucker BJ, Sawyers CHL et al. A phase 2 study of imatinib in patients with relapse or refractory Philadelphia chromosome-positive lymphoid leukemias. Hematol J 2002; 3:2–6. <https://doi.org/10.1038/sj.thj.6200151>
42. Pinilla – Ibarz J, Cathcart K, Korontsvit T et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95:1781–7.
43. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duffos N et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI 571, and they can pre-exist to the onset of treatment. Blood 2002; 100:1014–8. <https://doi.org/10.1182/blood.V100.3.1014>
44. Rowley JD. A new consistent abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290–3. <https://doi.org/10.1038/243290a0>
45. Savage DG, Antman KH. Imatinib mesylate – a new oral target therapy. N Engl J Med 2002; 346:683–93. <https://doi.org/10.1056/NEJMra013339>
46. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crises: results of a phase II study. Blood 2002; 99:3530–9. <https://doi.org/10.1182/blood.V99.10.3530>
47. Shindler T, Bornmann W, Pellicena P et al. Structural mechanisms for STI 571 inhibition of abelson tyrosine kinase. Science 2000; 289:1938–42. <https://doi.org/10.1126/science.289.5486.1938>
48. Sun X, Layton JE, Elefanty A et al. Comparison of effects of the tyrosine kinase inhibitors AG 957, AG 490, and STI 571 on BCR-ABL – expressing cells, demonstrating synergy between AG 490 and STI 571. Blood 2001; 97:2008–15. <https://doi.org/10.1182/blood.V97.7.2008>
49. Talpaz M, Kantarjian HM, Mc Credie K et al. Interferon – Alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991; 114:532–8. <https://doi.org/10.7326/0003-4819-114-7-532>
50. Talpaz M, McCredie KB, Mavligit GM et al. Leukocyte interferon-induced myeloid cytoreduction in myelogenous leukemia. Blood 1983; 62:689–92.
51. Talpaz M, Silver RT, Drucker BJ. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928–37. <https://doi.org/10.1182/blood.V99.6.1928>
52. Tipping AJ, Mahon FX, Lagarde V et al. Restoration of sensitivity to STI 571 – resistant chronic myeloid leukemia cells. Blood 2001; 98:3864–7. <https://doi.org/10.1182/blood.V98.13.3864>
53. Tsao AS, Kantarjian H, Talpaz M. STI 571 in chronic myelogenous leukemia. Br J Haematol 2002; 119:15–24. <https://doi.org/10.1046/j.1365-2141.2002.03899.x>
54. Voglová J, Poznarová A, Chrobák L et al. Imatinib mesylát (Glivec) v léčbě chronické myeloidní leukemie. Vnitř Lék 2003;43 (in press).
55. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI 571 in BCR/ABL – transformed hematopoietic cell lines. Blood 2000; 95:3498–505.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive